Autoimmune Hemolytic Anemia
A condition where your immune system creates antibodies that attack and prematurely destroy your own red blood cells, causing anemia and jaundice.
Emergency Management: Severe, life-threatening anemia (e.g., Hb < 5 g/dL) requiring emergency uncrossmatched or 'least incompatible' packed RBC transfusion. The blood bank MUST be told the patient has AIHA so they don't delay life-saving blood while hunting for a 'perfectly matched' unit that doesn't exist.
Autoimmune Hemolytic Anemia (AIHA) is a rare, acquired disorder in which the immune system produces autoantibodies that mistakenly target and destroy the patient's own red blood cells (RBCs), leading to a shortened RBC lifespan and subsequent anemia. It is broadly classified into Warm AIHA (driven by IgG) and Cold AIHA (driven by IgM), based on the temperature at which the antibodies best bind to RBCs.
Detailed Overview
In Warm AIHA (approx 70-80% of cases), IgG antibodies coat RBCs at normal core body temperature (37°C). As these coated RBCs pass through the spleen, splenic macrophages partially bite off the antibody-coated membrane. The damaged RBC becomes a rigid spherocyte, which gets trapped and fully destroyed in the spleen on subsequent passes (extravascular hemolysis). In Cold AIHA (Cold Agglutinin Disease), IgM antibodies bind to RBCs in cooler peripheral extremities (0-4°C). IgM efficiently activates the complement cascade. As RBCs return to the warmer core, IgM falls off, but the complement (C3b) remains. This can lead to intravascular destruction by the membrane attack complex or extravascular destruction in the liver by Kupffer cells.
Epidemiology & Demographics
Rare disease with an incidence of 1-3 per 100,000 per year. Warm AIHA is more common in adults (females > males) and frequently associated with systemic autoimmune diseases or lymphoid malignancies. Cold AIHA is often seen in older adults or post-mycoplasma infection in younger patients.
Etiological Mechanism
Idiopathic in about 50% of cases. Secondary cases are triggered by underlying lymphoproliferative disorders, autoimmune diseases, infections, or drugs.
Primary Causes
Warm AIHA is often secondary to SLE (Lupus), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, or drugs (e.g., Penicillin, Methyldopa). Cold AIHA is frequently secondary to Mycoplasma pneumoniae, Epstein-Barr Virus (EBV), or Waldenström's macroglobulinemia.
Loss of immune tolerance leads to autoantibody production against RBC surface antigens (e.g., Rh proteins in Warm AIHA, I/i antigens in Cold AIHA).
Warm AIHA: IgG coats RBCs -> Fc receptors on splenic macrophages recognize IgG -> partial phagocytosis -> spherocyte formation -> loss of deformability -> destruction in splenic cords (Extravascular).
Cold AIHA: IgM binds RBCs in cold extremities, bringing them together (agglutination, causing acrocyanosis). IgM fixes complement. Complement C3b opsonizes the RBC, leading to destruction in the liver, or terminal complement (C5-C9) causes direct lysis in the bloodstream (Intravascular).
Diagnostic Criteria & Guidelines
Diagnosis requires evidence of hemolysis (low Hb, high retics, high LDH, low haptoglobin) PLUS a positive Direct Antiglobulin Test (DAT / Direct Coombs test) demonstrating IgG and/or C3 on the patient's RBCs.
For Warm AIHA: High-dose systemic corticosteroids are the cornerstone (e.g., Prednisone 1-1.5 mg/kg/day). Often combined with folic acid supplementation to support high bone marrow RBC production. For Cold AIHA: Avoidance of cold temperatures is primary. Corticosteroids and splenectomy are INEFFECTIVE for Cold AIHA (because destruction is complement-mediated in the liver/vessels, not IgG in the spleen). First-line targeted therapy for Cold AIHA is Rituximab (anti-CD20 monoclonal antibody) 375 mg/m2 weekly for 4 weeks.
Second-Line & Adjunctive Therapy
For Warm AIHA (steroid-refractory or dependent): Rituximab is standard second-line. Splenectomy is third-line, reserved for refractory cases (removes the primary site of RBC destruction). Immunosuppressants like Azathioprine or Cyclosporine may be used. For Cold AIHA: Sutimlimab (a C1s complement inhibitor) is FDA-approved to halt hemolysis and reduce transfusion needs in CAD.
Surgical & Procedural Management
Splenectomy (for Warm AIHA only). Requires prior vaccination against encapsulated organisms (Strep pneumoniae, H. influenzae, N. meningitidis).
Patient Counseling & Advice
For Cold AIHA, explicitly warn that drinking cold beverages can trigger painful throat spasms or acute hemolysis. For all AIHA, explain that blood transfusions are inherently difficult because the autoantibodies will attack donor blood just like their own, making finding 'compatible' blood nearly impossible (crossmatch will always be positive).
Follow-Up & Monitoring Schedule
Frequent CBCs during tapers of corticosteroids to catch early relapses. Monitor for steroid-induced complications (diabetes, osteoporosis).
Preventive Strategies
No specific prevention. Prophylactic anticoagulation is often recommended during severe acute flares due to the high risk of thrombosis.
Warm AIHA often requires long-term therapy but has good survival rates; roughly 30% achieve long-term remission after steroids/Rituximab. Cold AIHA tends to be a chronic, indolent disease managed by lifestyle modifications.